mp.weixin.qq.com·· 14 hours agoScore83
Gan & Lee's Bofanglutide GRADUAL-3 Hits Primary Endpoint, Monthly Dosing Maintains Weight Loss Better Than Placebo at 24 Weeks
In brief
Gan & Lee Pharmaceuticals announced on October 27, 2026 that the Phase IIIb GRADUAL-3 study met its primary endpoint. After 24 weeks of once-monthly bofanglutide (GZR18) maintenance treatment, weight control was significantly superior to placebo.
Source: mp.weixin.qq.com · mp.weixin.qq.com